Abbott Laboratories (ABT)

In the past six months, Abbott Laboratories' stock has experienced several events. As of July 18, 2025, the share price was $123.69, a 21.23% increase from July 19, 2024. Q2 2025 earnings were released on July 17, 2025, with sales beating expectations but profit meeting estimates, leading to a stock slump. Abbott launched the FreeStyle Libre 3 Plus Glucose Sensor Technology in Canada on July 8, 2025. In April 2024, the FDA approved TriClip. In February 2024, Insulet's Omnipod 5 received CE Mark approval to be integrated with Abbott's FreeStyle Libre 2 Plus sensor. In January 2024, Abbott launched the Protality brand. Q1 2024 earnings showed strong underlying base business performance, and the company raised its full-year guidance. The decline in COVID-19 testing sales has impacted overall reported sales growth.

There are no significant seasonal aspects to Abbott Laboratories' business. Demand for Abbott's products and services is generally influenced by economic growth and healthcare spending, health consciousness and lifestyle changes, public awareness and education campaigns, innovation and new product development, regulatory changes, and supply chain stability.

Abbott Laboratories, founded in 1888 and headquartered in Abbott Park, Illinois, is a global healthcare company involved in the discovery, development, manufacturing, and sale of healthcare products. Abbott operates within the Healthcare sector and the Medical Devices and Pharmaceutical industries. The company's business is segmented into Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices, which includes Diabetes Care, Rhythm Management, Electrophysiology, Heart Failure, Vascular, Structural Heart, and Neuromodulation.

Abbott Laboratories has a significant global presence, serving more than 160 countries worldwide, with approximately 60% to 62% of its sales derived from outside the United States. The company has a strong presence in regions such as Asia Pacific, the Middle East, Africa, Europe, and the Americas. Key operational and manufacturing sites are located in the San Francisco Bay Area, Wiesbaden in Germany, Donegal, Ireland, and Witney, United Kingdom. Abbott also has a presence in various Latin American countries and its Asia-Pacific commercial operations hub for Diabetes Care is in Singapore.

Abbott Laboratories has a strong brand reputation, built over its long history in the healthcare industry, known for its quality and reliability. Abbott has continued to emphasize its commitment to sustainability and health equity, taking the top spot on the 2023 Dow Jones Sustainability Index (DJSI) for the 11th year. The company's 2030 Sustainability Plan focuses on access and affordability, transforming care for chronic diseases, and advancing health equity. In the first quarter of 2023, the company was still recovering market share in its infant formula business following a voluntary recall of certain products in the prior year.

Abbott Laboratories is heavily dominated by institutional owners, who hold approximately 77.37% to 79% of the shares. Insiders own around 1.14%, and retail investors hold about 20% to 21.49%. Major institutional shareholders include Vanguard Group Inc, BlackRock, Inc., and State Street Corp.